Evidence map›Paper›PMID 39062071›Full record

ArticleBiomedicines2024

Anti-Cancer Activities of Nano Amorphous Calcium Phosphates toward Premalignant and Oral Cancer Cells.

Evelina Herendija, Milica Jakšić Karišik, Jelena Milašin, Miloš Lazarević, Nenad Ignjatović

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Evelina HerendijaMultidisciplinary PhD Studies, University of Belgrade, Studentski Trg 1, 11000 Belgrade, Serbia.
Milica Jakšić KarišikImplant-Research Center, School of Dental Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.ORCID 0000-0003-1114-0829
Jelena MilašinImplant-Research Center, School of Dental Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.ORCID 0000-0002-6225-7210
Miloš LazarevićImplant-Research Center, School of Dental Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia.ORCID 0000-0003-1330-5332
Nenad IgnjatovićInstitute of Technical Sciences of the Serbian Academy of Science and Arts, Knez Mihailova 35/IV, 11000 Belgrade, Serbia.ORCID 0000-0002-5749-094X

Funding

Ministry of Science, Technological Development and Innovation of the Republic of Serbia 451-03-66/2024-03/ 200129Ministry of Science, Technological Development and Innovation of the Republic of Serbia 451-03-66/2024-03/200175Science Fund of the Republic of Serbia 7750038
6 · The paper itself

Abstract

Despite advancements in treatment, the squamous cell carcinoma (OSCC) patient survival rate remains stagnant. Conventional therapies have limited effectiveness, necessitating novel agents. Our study aims to synthesize and characterize amorphous calcium phosphate nanoparticles (nACPs), assess their potential cytotoxic effects on premalignant and malignant OSCC cells, and investigate possible mechanisms of action. The morphological features of nACP were investigated by field emission scanning coupled with energy dispersive spectroscopy (EDS), Fourier transform infrared spectroscopy (FTIR), and particle size distribution (PSD). Then, we examined the effect of nACPs on nanoparticle uptake, cell adhesion, viability, invasion ability, cell cycle, and gene expression. nACP uptake was dose-dependent, induced limited selectivity in cytotoxicity between healthy and malignant cells, and affected cellular adhesion and invasion. Early apoptosis was the predominant type of cell death. The nACP effect on viability was verified by alterations in the genes associated with apoptosis and proliferation. A high concentration of nACP was shown to arrest the cell cycle progression in the G0/G1 phase of both malignant and premalignant cells. This type of nACP justifies the development of a strategy for its potential use as an anti-cancer agent and/or anti-cancer active carrier for various drugs in oral cancer treatments.

Indexed as

amorphous calcium phosphateanti-cancer effectdysplasiaoral cancer

Identifiers

PMID39062071
PMCPMC11274579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.